AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00637481 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00980213 — intervention group
Intervention type: DRUG
Intervention: sunitinib
Description: sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
Study NCT02138994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science Wound Gel
Study NCT02138994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple Antibiotic Ointment Neosporin
Description: Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months
Study NCT02108574 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Filter
Study NCT02108574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhinix Nasal Filter
Study NCT02897206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: A wide-spectre antibiotic from the carbapenem group
Study NCT02897206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An imipenem-matching placebo
Study NCT01801800 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: T Diclofenac 50 mg twice daily for 12 months
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: T Methimazole 5 mg 3x2 for 18 months
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methimazole
Description: T Methimazole 5 mg 3x2 for 18 months
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-thyroxin
Description: L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: L-thyroxin
Description: L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol
Description: T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
Study NCT01458600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol
Description: T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
Study NCT00532116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 6mg
Description: STS 6mg/24hr
Study NCT00532116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 12mg
Description: EMSAm 12mg/24Hr
Study NCT01507506 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.
Study NCT01507506 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.
Study NCT03908606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Supra and subgingival scaling and root planing.
Study NCT01439906 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical correction of the deformity
Description: Three different surgical techniques are used:~* lumbar fusion vs thoraco-lumbar fusion~* iliac fixation vs fixation to the sacrum~* posterior + interbody fusion vs posterior interbody fusion
Study NCT02861820 — intervention group
Intervention type: DEVICE
Intervention: MRI: Brain Imaging Data Collection
Description: This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
Study NCT02150798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat and low carbohydrate diet
Description: high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
Study NCT02150798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Control diet. At baseline and at 2 month of following, the variables that were evaluated,
Study NCT04320446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test in the morning
Description: The exercise test was performed between 8 a.m and 11 a.m
Study NCT04320446 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Test in the morning
Description: The exercise test was performed between 8 a.m and 11 a.m
Study NCT04320446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test in the afternoon
Description: The exercise test was performed between 5 p.m. and 8 p.m.a
Study NCT04320446 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Test in the afternoon
Description: The exercise test was performed between 5 p.m. and 8 p.m.a
Study NCT03729960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LENA recorder
Description: The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
Study NCT02212392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
Study NCT02838303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Organophosphate
Description: Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
Study NCT02838303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Multineem, WHO Class U: Unlikely to present acute hazard in normal use
Study NCT04207970 — intervention group
Intervention type: OTHER
Intervention: Adapted Structured Clinical Management
Description: Adapted form of a previous Evidence Based Treatment- adapted to local context, in light of input from service-users and commissioners.
Study NCT04478955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer test
Description: Tear tests Meibomian gland grading test
Study NCT01101932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
Study NCT01101932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
Study NCT01101932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515 Tablet
Description: Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
Study NCT04648072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: As previously described.
Study NCT04648072 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor Canal Block
Description: As previously described.
Study NCT00985491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobarrier Liner
Description: Medical device placed endoscopically in the duodenum
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (rabbit)
Description: Given intravenous (IV) prior to transplant on Days -14, -13, -12.
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
Study NCT04648072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular Injection
Description: As previously described.
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV infusion prior to transplant on Day -9.
Study NCT04648072 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periarticular Injection
Description: As previously described.
Study NCT02468323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive regular spinal anesthesia
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV prior to transplant on Days -2 and -1.
Study NCT02790515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
Study NCT03566771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
Study NCT03566771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLOSS
Description: Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
Study NCT02150551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived mesenchymal stromal cells
Description: This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; \<18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : >34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
Study NCT04413656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ablation
Description: Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
Study NCT04413656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
Study NCT02479685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques
Description: To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
Study NCT02479685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques
Description: To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
Study NCT00962533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: telbivudine, 600mg, oral, daily
Study NCT00962533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telbivudine
Description: telbivudine, 600mg, oral, daily
Study NCT04011566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ShuntCheck
Description: The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
Study NCT03490591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted hand rehabilitation
Description: Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
Study NCT00680355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: golden rice
Description: An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene
Study NCT00680355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: corn oil 0g
Description: 0 g of corn oil in the golden rice meal
Study NCT00680355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: corn oil 10g
Description: 10g corn oil in the golden rice meal
Study NCT00680355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: coren oil 5 g
Description: golden rice meal with 5 g corn oil
Study NCT01772524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403
Study NCT01772524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04187144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
Study NCT04187144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching nitrofurantoin
Description: Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
Study NCT04187144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
Study NCT04187144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching gepotidacin
Description: Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
Study NCT00464373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
Study NCT00464373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4ml NaCl 0.9%
Study NCT00808613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optetrak PS
Description: Optetrak Posterior Stabilized total knee replacement
Study NCT00808613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optetrak Hi-Flex
Description: Optetrak Hi-Flex total knee replacement
Study NCT00996515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine, erlotinib
Description: Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
Study NCT00996515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib PO and Vidaza IV
Description: Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
Study NCT02663804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Study NCT01214759 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Truvada
Description: Tenofovir 200mg/emtricitabine 300mg once a day
Study NCT01214759 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Description: Raltegravir 400mg twice a day
Study NCT03055728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid strep antigen detection test
Description: Pharyngeal swab for rapid antigen detection of streptococcus
Study NCT03055728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: throat culture
Description: Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
Study NCT02330666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mission Possible: Parents & Kids Who Listen
Description: MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
Study NCT01892436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).
Study NCT00042965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00042965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT03998098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oxygen Saturation (Oximetry)
Description: Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers
Study NCT03998098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate (Pulse)
Description: Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers